



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## 1p/19q Deletions for Glioma

### Alternative Name

1/19 Co-deletion, 1p/19q Tricolor Deletion

### Methodology

FISH

### Test Description

**Probes:** 1p36/1p12/1q25 | 19q13/19q11q12/19p13

**Disease(s):** Oligodendroglioma

This assay employs one centromeric probe and two distal probes per chromosome to detect and differentiate whole-arm vs partial 1p and 19q deletions, and to detect polysomy.

### Clinical Significance

Testing for 1p and 19q deletions in glial brain tumors, specifically oligodendrogliomas, has diagnostic and prognostic value. Whole-arm deletions of chromosomes 1p and 19q (with concurrent IDH1 or IDH2 mutation) are diagnostic for oligodendroglioma according to WHO classification. Co-deletion of both the 1p and 19q regions in adult oligodendroglioma patients is associated with improved response and longer survival in patients receiving radiation and/or chemotherapy. Results can help distinguish the oligodendroglioma subtype of diffuse gliomas from astrocytomas and from other tumor types with similar morphology such as clear cell ependyomas, central or extraventricular neurocytomas, and dysembryoplastic neuroepithelial tumors (DNETs). Partial deletions may be seen in high-grade glioblastomas. Polysomy in the presence of whole-arm co-deletions may occur in anaplastic oligodendroglioma.

### Specimen Requirements

- **Paraffin Block:** Send paraffin block. Also send circled H&E slide for tech-only (required).
- **Cut Slides:** Send 4 unstained slides cut at 4-5 microns plus H&E slide (required). Circle H&E slide for tech-only.

### Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

88374x2 automated or 88377x2 manual. Codes may differ if manual analysis is performed.

### New York Approved

Yes

### Level of Service

Technical, Global

### Turnaround Time

3-5 days

## References

1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol*. DOI 10.1007/s00401-016-1545-1 Published online May 9, 2016

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 050924